184 related articles for article (PubMed ID: 32557810)
21. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Alvarez-Larrán A; Pereira A; Arellano-Rodrigo E; Hernández-Boluda JC; Cervantes F; Besses C
Br J Haematol; 2013 Jun; 161(6):865-71. PubMed ID: 23577924
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
[TBL] [Abstract][Full Text] [Related]
23. [Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia].
Pósfai É; Marton I; Nemes A; Borbényi Z
Orv Hetil; 2015 Apr; 156(14):558-63. PubMed ID: 25819149
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
25. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ;
J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096
[TBL] [Abstract][Full Text] [Related]
26. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
[TBL] [Abstract][Full Text] [Related]
28. [Primary thrombocythemia: diagnosis and therapy].
Petrides PE
Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
[TBL] [Abstract][Full Text] [Related]
29. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
30. Essential thrombocythaemia in children: is a treatment needed?
Randi ML; Putti MC
Expert Opin Pharmacother; 2004 May; 5(5):1009-14. PubMed ID: 15155103
[TBL] [Abstract][Full Text] [Related]
31. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
32. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Campbell PJ; Bareford D; Erber WN; Wilkins BS; Wright P; Buck G; Wheatley K; Harrison CN; Green AR
J Clin Oncol; 2009 Jun; 27(18):2991-9. PubMed ID: 19364963
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
Alvarez-Larrán A; Angona A; Andrade-Campos M; Soledad Noya M; Teresa Gómez-Casares M; Cuevas B; Caballero G; García-Hernández C; García-Gutiérrez V; Palomino A; Ferrer-Marín F; Isabel Mata-Vázquez M; Moretó A; Magro E; Murillo I; Manuel Alonso-Domínguez J; María Guerra J; Guerrero L; María Raya J; Pérez-Encinas M; Carreño-Tarragona G; Fox L; Pastor-Galán I; Bellosillo B; Hernández-Boluda JC;
Br J Haematol; 2021 Mar; 192(6):988-996. PubMed ID: 32745264
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of essential thrombocythemia].
Costello R; O'Callaghan T; Sébahoun G
Rev Med Interne; 2005 Dec; 26(12):947-55. PubMed ID: 16122842
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Hernández-Boluda JC; Pereira A; Cervantes F; Gómez M; Arellano-Rodrigo E; Alvarez-Larrán A; Ferrer-Marín F; Kerguelen A; Márquez JA; Antelo ML; Besses C;
Ann Hematol; 2013 Jun; 92(6):771-5. PubMed ID: 23354997
[TBL] [Abstract][Full Text] [Related]
36. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
Birgegård G; Besses C; Griesshammer M; Gugliotta L; Harrison CN; Hamdani M; Wu J; Achenbach H; Kiladjian JJ
Haematologica; 2018 Jan; 103(1):51-60. PubMed ID: 29079600
[TBL] [Abstract][Full Text] [Related]
37. When and how to treat essential thrombocythemia.
Barbui T; Finazzi G
N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
[No Abstract] [Full Text] [Related]
38. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
39. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
[TBL] [Abstract][Full Text] [Related]
40. Pharmacotherapy of essential thrombocythaemia: economic considerations.
Griesshammer M; Langer C
Expert Opin Pharmacother; 2003 Sep; 4(9):1499-505. PubMed ID: 12943479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
